Purpose The purpose of this paper is to compare the uptake of two clinically promising positron emission tomography (PET) hypoxia targeting agents, 124 I-iodoazomycin galactopyranoside ( 124 I-IAZG) and 18 F-fluoromisonidazole ( 18 F-FMISO), by dynamic microPET imaging, in the same rats bearing liver tumors and peritoneal metastasis. Methods Morris hepatoma (RH7777) fragments were surgically implanted into the livers of four nude rats. Tumors formed in the liver and disseminated into the peritoneal cavity. Each rat had a total of two to three liver tumors and peritoneal metastasis measuring 10-15 mm in size. Animals were injected with 18 F-FMISO, followed on the next day (upon complete 18 F decay) by 124 I-IAZG. The animals were imaged in list mode on the microPET system from the time of injection of each tracer for 3 h and then again at 6 h and 24 h for the long-lived 124 I-IAZG tracer (4.2-day half-life). Micro computed tomography (CT) scans of each rat were performed for co-registration with the microPET scans acquired with a liver contrast agent, allowing tumor identification. Regions of interest (ROIs) were drawn over the heart, liver, muscle, and the hottest areas of the tumors. Time-activity curves (TACs) were drawn for each tissue ROI. Results The 18 F-FMISO signal increased in tumors over the 3-h time course of observation. In contrast, after the initial injection, the 124 I-IAZG signal slowly and continuously declined in the tumors. Nevertheless, the tumor-to-normaltissue ratios of 124 I-IAZG increased, but more slowly than those of 18 F-FMISO and as a result of the differentially faster clearance from the surrounding normal tissues. These pharmacokinetic patterns were seen in all 11 tumors of the four animals. Conclusions 18 F-FMISO localizes in the same intra-tumor regions as 124 I-IAZG. The contrast ratios (tumor/background) reach similar values for the two hypoxia tracers, but at later times for 124 I-IAZG than for 18 F-FMISO and, therefore, with poorer count statistics. As a consequence, the 18 F-FMISO images are of superior diagnostic image quality to the 124 I-IAZG images in the Morris hepatoma McA-R-7777 tumor model.
high hypoxia levels have been reported in patients with colorectal liver metastasis based on the post-surgical analysis of tumor specimens [3] . The ability to preoperatively and noninvasively assess liver tumor hypoxia would offer three potential benefits: (i) the identification of tumor heterogeneity for biologically based focal ablative therapies (e.g., intensity-modulated radiotherapy or high-focus ultrasound therapy) [4] ; (ii) the selection of patients who would benefit from newly developed hypoxia-targeted treatment regimens [5] ; and (iii) a prognostic marker of treatment outcome [6] .
A variety of different hypoxia markers [7] [8] [9] [10] [11] [12] have been labeled with positron-emitting radionuclides to enable the noninvasive imaging of tumor hypoxia by positron emission tomography (PET). While many of these labeled markers exhibit promising results in vitro, and also in vivo in flank tumor models, their utility in more clinically relevant orthotopic tumor models has not been studied. The imaging of hypoxia in intra-abdominal tumors is problematic because of high tracer background levels in the abdomen [12] [13] [14] [15] . Choosing the appropriate imaging tracer will be essential for the success of clinical trials using imaging as a biological (e.g., hypoxia) tumor biomarker. Understanding the relative advantages and disadvantages of various tracers is challenging, since most investigators explore a single tracer and aspects of their study designs, such as the tumor models and imaging time points used, vary substantially. Comparison is most effective when multiple tracers are tested on identical tumor models, using identical imaging protocols [16] .
In the present study, we compared uptake of 124 Iiodoazomycin galactopyranoside ( 124 I-IAZG) with the uptake of fluorine-18-labeled fluoromisonidazole ( 18 F-FMISO; half-life 1.8 h), as assessed by dynamic microPET imaging, testing both tracers in the same rats bearing liver tumors and peritoneal metastasis [17, 18] . The selection of 124 I-IAZG for our study was based on hypoxia tracer uptake in other tumor animal models, where the potential advantages of delayed PET imaging with 124 I was demonstrated [14] . 18 F-FMISO was chosen for comparison because it has been extensively evaluated in the United States (University of Washington, WA) and in Europe (University of Tuebingen, Germany) and, at present, is considered to be the standard for PET hypoxia imaging [19] [20] [21] .
Materials and methods

Animal tumor model
Animal studies were performed in conformity with all applicable policies, procedures, and regulatory requirements of the Institutional Animal Care and Use Committee (IACUC), the Research Animal Resource Center (RARC) of the Memorial Sloan-Kettering Cancer Center (MSKCC), and the National Institutes of Health (NIH)'s "Guide for the care and use of laboratory animals." Six-to eight-week-old nude rats were purchased from Charles River Laboratories (Wilmington, MA), two were kept per cage, and were allowed food and water ad libitum. All animal procedures were performed under anesthesia by the inhalation of 2% isoflurane. The syngeneic rat hepatocellular carcinoma cell line Morris hepatoma McA-R-7777 was obtained from the American Type Culture Collection (Rockville, MD) and was maintained in the Dulbeccos modified Eagles medium (DMEM, Memorial Sloan-Kettering Cancer Center media lab, New York, NY) supplemented with high glucose (4.5 g/l), 10% fetal bovine serum, and 5 mmol/l L-glutamine. A subcutaneous flank tumor was established by injecting roughly 5 × 10 6 Morris hepatoma cells (RH7777) in phosphate buffer solution (PBS) in a total volume of 50 μl and the animal was monitored until the tumor reached a size of 1 cm. The animal was sacrificed and the tumor was harvested and cut to small fragments of size ∼2 mm 3 . Other nude rats were anesthetized and opened via midline incision. With a pointed #11 blade scalpel lying flat on the liver surface, a 1-cm-long tunnel was punctured into the left liver lobe horizontally just beneath the liver capsule and an approximately 2-mm 3 tumor fragment was inserted into the resulting superficial pouch. After further implantations into the middle and right liver, the animals were closed and returned to their cages. Tumor growth was monitored with a dedicated small animal ultrasound system (Vevo 770™, VisualSonics, Toronto, Canada). When implanted tumor fragments disseminated into the peritoneal cavity and grew as peritoneal implants, they were considered to mimic peritoneal metastasis and their detection by PET imaging with the two hypoxia tracers was also compared. The liver tumors and peritoneal metastasis that result from the procedure described above consistently feature extensive hypoxic areas throughout the entire tumor (pO 2 <0.5 mmHg), as demonstrated by immunohistochemistry staining with the well-established hypoxia tracers pimonidazole and EF5 in previous studies (C.C.R., unpublished data, 2006). Radioisotope production 18 F-fluoride was produced in-house on an EBCO TR19/9 cyclotron (EBCO Technologies, Vancouver, Canada) capable of accelerating protons to a maximal energy of 19 MeV. O-water target in a small-volume titanium chamber. 18 F-FMISO was prepared as previously reported [22] , with minor modifications. IAZG was radiolabeled with 124 I as previously described by Zanzonico et al. [14] , with exchange labeling between the nonradioactive iodoazomycin nucleoside and 124 I-NaI (Eastern Isotopes, Somerset, NJ), and purification by AgCl-treated celite/anion exchange chromatography [10] . Radiochemical purity, evaluated by thin-layer chromatography, was >99%.
FMISO (1-(2-nitroimidazole)-3-fluoro-2-propanol) is a compound with a 2-nitroimidazole (azomycin) group coupled with 3-fluoro-2-propanol. IAZG (1-(6-deoxy-6-iodo-beta-D-galactopyranosyl) 2-nitroimidazole) is a "sugar-coupled" 2-nitroimidazole (azomycin) derivative. A significant difference between these two hypoxia markers is their lipophilicity [23] . According to Sorger et al. [23] , the partition coefficients, which are frequently used as lipophilicity indicators, for FMISO and IAZA are 2.60 and 4.98, respectively. And according to Engelhardt et al. [22] , the partition coefficients for IAZA and IAZG are 3.85 and 0.63, respectively.
Dynamic hypoxia microPET-CT imaging
The study was performed on four rats, each with a total of two to three liver tumors and peritoneal metastasis of 10-15 mm in size. A two-day imaging procedure (described below) was performed on one pair of rats and was repeated three weeks later on a second pair of rats. Imaging was performed using an R4 or a Focus 120 microPET™ dedicated small-animal PET scanner (Concorde Microsystems Inc., Knoxville, TN). The rats were maintained under 2% isofluorane anesthesia in oxygen at a flow rate of 2 L/min during the entire scanning period. During imaging, the body temperature of the anesthetized animals was stabilized with a heat lamp. With a single bed position centered on the animals' livers, the lower half of the thorax (including the heart) and the upper half of the abdomen were covered by the scanners. On day one, two rats were injected with 74 MBq (2 mCi) of 18 F-FMISO (t 1/2 =1.8 h) intravenously. Twenty-four hours later, after the 18 F-FMISO activity had decayed to a negligible fraction, 37 MBq (1 mCi) of 124 I-IAZG was injected into the same two rats. The long half-life of 124 I (t 1/2 =4.2 d) permitted additional acquisitions of 1-h duration at 6 h (all four rats) and at 24 h (two of four rats) after injection.
Three-dimensional (3D) list-mode data were acquired using an energy window of 350-700 keV and a coincidence timing window of 6 ns. These data were then sorted into two-dimensional (2D) histograms by Fourier re-binning using a span of 3 and a maximum ring difference of either 32 (R4) or 47 (Focus 120). Transverse images were reconstructed by filtered back-projection using a ramp filter with a cut-off frequency equal to the Nyquist frequency in either a 128×128×64 matrix (R4) or a 128×128×94 matrix (Focus 120) comprised of 0.866×0.866×0.866-mm voxels.
The image data were corrected for: (a) nonuniformity of scanner response using a uniform cylinder-source-based normalization; (b) dead time count losses using a singlecount-rate-based global correction; (c) physical decay to the time of injection; and (d) the 124 I branching ratio. There was no correction applied for attenuation, scatter, or partialvolume averaging. The count rates in the reconstructed images were converted to activity concentration (% of injected dose per gram of tissue, %ID/g) using a system calibration factor (μCi/ml/cps/voxel) derived from the imaging of a rat-size phantom filled with a uniform aqueous solution of 18 F. The measured reconstructed spatial resolutions of the R4 and Focus 120 are~2.3 mm and ∼1.6 mm full-width halfmaximum (FWHM), respectively, for 18 F at the center of the field of view; the corresponding values for 124 I are 0.3-0.4 mm larger. The response (observed count rate versus activity) of the R4 and of the Focus 120, measured using 18 F, is linear up to a total activity of ∼1.5 mCi in the field of view (FOV). Only about half of a rat is within the scanner's FOV, however. Therefore, for a tail vein injection of 2 mCi, no more than about 1 mCi is presumably within the FOV.
To allow for the anatomical orientation of the PET images, computed tomography (CT) scans of each rat were performed for co-registration with each PET scan. For this, six hours prior to the first CT scan, the small animal CT liver contrast agent Fenestra LC (Fenestra LC, Alerion Biomedical, San Diego, CA) was administered [24] . CT scans were performed on a dedicated small animal CT scanner (X-Spect, Gamma Medica, Chicago, IL). PET and CT image fusion and image analysis were performed using ASIPro software (Concorde Microsystems Inc., Knoxville, TN). For each dynamic data set, regions of interest (ROIs) were drawn over the heart (to provide information on the delivered radioactivity), liver, muscle, and the hottest areas of the tumors. Time-activity curves (TACs) were drawn for each tissue ROI and presented on a single graph. For the sake of clarity, error bars have been excluded from the graphs. However, the magnitude of the data variability can be seen by the fluctuation between adjacent time points. Furthermore, ROIs were drawn on the 6-h and 24-h static 124 I-IAZG PET images, and decay-corrected measured activities were added to the TAC data.
Results
The PET imaging of both 18 F-FMISO and 124 I-IAZG tracers demonstrated the targeting of tumor hypoxia. Figure 1 shows representative 3-h TACs for 18 F-FMISO and 124 I-IAZG in tumor, liver, and muscle tissue in the same animal (rat #1). Figure 2 shows the %ID/g in the three tissue types of all animals for both tracers at 3 h, as well as for 124 I-IAZG at 6 h and 24 h. There were distinct differences in the TACs of the two hypoxia tracers. The signal increase for 18 F-FMISO in tumor tissue suggests the accumulation of the tracer within tumor hypoxia over time and resembles the kinetic uptake profiles reported by Thorwarth et al. in clinical 18 F-FMISO studies [25] . In contrast, 124 I-IAZG demonstrated a continuous but slow signal decrease in tumor tissue over time. However, the rate of signal decline in the surrounding normal liver and muscle tissue was faster than in the tumor, resulting in a gradually increasing tumor-to-background ratio (Figs. 3 and 4) . The described patterns were seen in all 11 tumors of the four animals. Figure 5 shows various frames over time of the dynamic PET studies of an animal for both tracers, as well as the 124 I-IAZG at 6-h post-injection. Figure 6 shows the last 10-min frames from the initial (3-h) dynamic image for both tracers in another representative animal. Additionally, for 124 I-IAZG, a longer 35-min frame from the end of the 3-h acquisition period was reconstructed to compensate for a possible lower signal-to-noise ratio due to the lower administered dose of Signal intensities in the intestines varied substantially for both tracers from far below and up to three times higher than tumor levels. Signal intensity levels varied not only between animals, but also within animals, depending on region and time. Most of the activity observed in the gastrointestinal tract is associated with stools, as reported in the paper by Zanzonico et al. [14] .
Discussion
There is growing evidence to support the contention that tumor hypoxia is a major prognostic indicator of treatment outcome, regardless of the type of therapy [1, 2, 6] . As a consequence, methods to noninvasively determine the tumor hypoxic fraction are of immediate clinical relevance. Surrogate magnetic resonance (MR) methods to measure hypoxia, such as lactate spectroscopy [26] or 19 F MRI relaxometry of hexafluorobenzene [27, 28] , are under development. However, the focus of our paper was on PET imaging. Since the best hypoxia-specific PET radiotracer is not known, we performed a comparison of two promising radiolabeled nitroimidazoles, one using a short 18 F and the second a long-lived 124 I isotope, allowing late imaging. Both hypoxia radiotracers have demonstrated a high degree of pO 2 specificity in uptake and retention through cell culture studies in our labs and by others [29] and in tumor-bearing animal model studies [14] . What is unique about our study is that it is the first reported comparison of these two tracers by dynamic PET imaging and was performed in an orthotopic model of hepatic carcinoma. The tracers were compared in the same four animals, reducing the possible effects of inter-tumor variability on the analysis.
The kinetic data curves from our study demonstrate the more rapid uptake and differentiation of 18 [14] . Note that the tumor-to-normal-tissue ratios at 3 h for 18 F-FMISO range from 1.2 to 2.3, higher for almost all tumors than the corresponding ratios for . This data suggests that the two tracers are comparable in their selective uptake in tumor hypoxia, in terms of tumorto-normal-tissue ratios. However, the later appearance of higher uptake ratios for 124 I-IAZG affects the PET image quality, since adequate hypoxia-specific ratios are only achieved when the absolute amount of tracer concentration is low. In contrast, at the optimum imaging time point for 18 F-FMISO (2 h to 3 h), the absolute amount of 18 F-FMISO concentration in the tumor is relatively high. This is clearly manifested in the PET images (Fig. 5) , where the higher counts from 18 F result in sharper and better diagnostic quality images than can be attained for the 124 I compound. 124 I is a positron emitter with a long half-life of 4.2 days, rendering it highly suitable for many radiotracer applications (such as those with IAZG), where tumor uptake or nonspecific signal clearance is slow. It has not been widely used because: (i) its positron fraction (0.24) is low compared to that of 18 F (0.97); (ii) its higher positron energy results in longer range emissions and poorer image resolution; and (iii) its decay scheme is complex and includes several high-energy gamma rays. However, measurements made under realistic conditions on several different PET scanners have shown that satisfactory imaging and quantitation can be achieved [30] . Line source resolution experiments showed that image spatial resolution was only slightly degraded (by less than 20%) on the clinical scanners studied, relative to the spatial resolution seen with 18 F, and concluded that quantitative imaging with 124 I was possible under realistic conditions with various PET scanners [30] . Resolution measurements have also been performed for 124 I on the R4 microPET scanner. The FWHM of the line spread function is 2.2 mm for 18 F and 3.3 mm for 124 I at the center of the field of view, and 3.2 mm for 18 F and 4.1 mm for 124 I at 2.5 cm from the center of the field of view, a degradation of only 25% [14] .
In conclusion, the findings of the present study show that 18 F-FMISO localizes in the same intra-tumor regions as 124 I-IAZG, and results in superior diagnostic image quality compared to 124 I-IAZG in the Morris hepatoma McA-R-7777 tumor model. The differences appear to be related to the greater positron fraction of 18 F, resulting in four-fold more counts (halving the Poisson statistical noise) per unit millicurie administered, and also to differences in the kinetic behavior of the hypoxia tracers. The 18 F-FMISO signal was observed to increase in the tumor over the 3-h time course of observation. In contrast, the 124 I-IAZG, after the initial blood bolus, slowly and continuously declined in the tumor. Tumor-to-normal tissue ratios improved slowly and steadily as a consequence of more gradual clearance from the tumor than from surrounding normal tissues. The reasons for the different kinetic behavior of 124 I-IAZG, relative to the expected slow accumulation seen with 18 F-FMISO, is not understood and further investigation will be necessary. Two possible explanations are de-iodination of the 124 I-IAZG tracer and differences in octanol-to-water partition coefficients of the respective hypoxia compounds, resulting in differences in the intra-and extra-cellular fractions of the tracers and in the consequent metabolic and elimination rates.
